Novartis halts early trial of promising blood cancer drug duo
NCT ID NCT04702425
Summary
This early-stage study aimed to find a safe dose and schedule for a new two-drug combination (VOB560 and MIK665) for patients whose non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma had returned or stopped responding to other treatments. The drugs were designed to work together to trigger cancer cell death. The main goal was to check for side effects and determine how much medicine patients could safely tolerate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
HUS, FIN-00029, Finland
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Sunto Gun, Shizuoka, 411 8777, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.